Precision biosciences stock.

Earnings for Precision BioSciences are expected to grow in the coming year, from ($0.29) to ($0.21) per share. Precision BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off prior year's report dates. Read More.Founders Derek Jantz, Jeff Smith, Matthew Kane. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Precision BioSciences, Inc. Stock Symbol NASDAQ:DTIL. Company Type For Profit. Contact Email [email protected]. Phone Number +1 919 314-5512. Precision …With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Precision Biosciences Inc stock received a consensus recommendation rating of an Overweight, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended DTIL as a Hold, whereas 3 deemed it a …DTIL Stock Analysis: Potential +608.72% Increase According to Analysts Forecasts. DTIL stock, the ticker symbol for Precision BioSciences Inc, closed at a price of 0.42 on September 19, 2023. The 5 analysts offering 12-month price forecasts for DTIL have a median target of 3.00, with a high estimate of 4.00 and a low estimate of 1.40.

DURHAM - Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and... | March 29, 2023

In a report released today, Justin Zelin from BTIG maintained a Buy rating on Precision BioSciences ( DTIL – Research Report ), with a price target of $6.00. The company’s shares opened today ...After the upgrade, the consensus from Precision BioSciences' five analysts is for revenues of US$37m in 2023, which would reflect a chunky 20% decline in sales compared to the last year of ...

Precision BioSciences shareholders are down 65% for the year, falling short of the market return. The market shed around 7.7%, no doubt weighing on the stock price. Shareholders have lost 23% per year over the last three years, so the share price drop has become steeper, over the last year; a potential symptom of as yet unsolved challenges.Aug 7, 2023 · DURHAM - Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced financial results for the second quarter ended June 30, 2023 and provided a business update. A Different Perspective. Precision BioSciences shareholders are down 73% for the year, falling short of the market return. The market shed around 12%, no doubt weighing on the stock price.If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.20 thg 11, 2020 ... Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® ...

Jun 27, 2022 · DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its common stock at an offering price of $1.39 per share, for total gross proceeds ...

Precision BioSciences, Inc. 0.3829. -0.0071. -1.82%. DURHAM, N.C., August 15, 2023--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in ...

13 hours ago · Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “ Efficient elimination of MELAS-associated m ... 7 ngày trước ... DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ...Nov 17, 2023 · In last trading session, Precision Biosciences Inc (NASDAQ:DTIL) saw 1.34 million shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $0.38 trading at $0.01 or 2.19% at ring of the bell on the day assigns it a market valuation of $45.46M. That closing price of DTIL’s stock is at a discount ... Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update. May 9, 2023 at 7:00 AM EDT. ... Weighted average shares of common stock outstanding were approximately 111.3 million for the quarter ended March 31, 2023, as compared to approximately 61.0 million for the quarter ended March 31, 2022.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

Get the latest information on Precision BioSciences Inc (DTIL), a biotechnology company that develops and commercializes genomic tests for cancer and other diseases. See its stock price, performance, financials, outlook, and news on Google Finance. Stock Price Forecast The 4 analysts offering 12-month price forecasts for Precision BioSciences Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.00.Stock Quote. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High.4 ngày trước ... Precision BioSciences Inc (DTIL:NASDAQ CM) の株価、株式情報、チャート、関連ニュースなど、企業概要や株価の分析をご覧いただけます。Research Precision BioSciences' (Nasdaq:DTIL) stock key valuation metrics while comparing it with its industry peers & market side by side. Dashboard Markets Discover Watchlist Portfolios Screener Precision BioSciences, Inc.When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.

Based on short-term price targets offered by five analysts, the average price target for Precision BioSciences comes to $3.00. The forecasts range from a low of $1.00 to a high of $5.00. The ...

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform …Justin Zelin’s Buy rating for the Precision BioSciences stock is based on several factors. The company, which primarily focuses on in-vivo gene editing, is heading towards advancing its ARCUS ...Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 24, 2023, Precision BioSciences, Inc. (the "Company") received a letter (the "Nasdaq Staff Deficiency Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, …Dec 4, 2023 · At the core of Precision Biosciences’ groundbreaking research is the ARCUS genome editing technology. This cutting-edge technology possesses unparalleled precision and versatility, enabling scientists to insert, delete, or repair disease-causing DNA in a wide range of genetic disorders. With the potential to revolutionize the field of genetic ... Precision will reimburse up to $7,500.00 per year for tuition and materials toward the pursuit of a degree. Employee Stock Purchase Program. Ability to purchase Precision BioSciences stock at a discount. Paid Time Off. Precision offers every full-time employee, regardless of level or tenure, 8 weeks of paid time off per year.These 4 analysts have an average price target of $6.75 versus the current price of Precision BioSciences at $0.525, implying upside. Below is a summary of how these 4 analysts rated Precision ...Stock analysis for Precision BioSciences Inc (DTIL:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Precision BioSciences with a $7.75 average price target. See the top stocks recommended by analysts >>Nov 6, 2023 · As of November 3, 2023, shares of Precision BioSciences were trading at $0.4256. Over the last 52-week period, the stock has experienced a decline of 68.38%. According to TipRanks, the average price target for DTIL is $2.58, with a high forecast of $4.00 and a low forecast of $1.00. In conclusion, investors will be closely monitoring Precision ...

Find the latest Precision BioSciences, Inc. (DTIL) stock quote, history, news and other vital information to help you with your stock trading and investing.

Track Precision Biosciences Inc (DTIL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Precision BioSciences (NASDAQ: DTIL), a biotechnology firm focusing on gene editing, announced that on November 21, the company's Compensation Committee authorized an inducement stock option for a new hire under the Nasdaq Listing Rule 5635(c)(4). The inducement, part of their Inducement Award Plan, allows the employee …Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update. November 7, 2023 at 7:00 AM EST. PDF Version ... Weighted average shares of common stock outstanding-basic and diluted 115,174,752 110,849,196 Precision Biosciences, Inc. Condensed Balance Sheets Data ...Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board ...In a report released on November 4, Justin Zelin from BTIG reiterated a Buy rating on Precision BioSciences (DTIL - Research Report), with a price target of $8.00.The companys shares closed last ...Weighted average shares of common stock outstanding were approximately 110.8 million for the quarter ended September 30, 2022, as compared to approximately 59.7 million for the quarter ended September 30, 2021. ... Precision BioSciences, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per …Dec 21, 2021 · DURHAM, N.C.--(BUSINESS WIRE)--Dec. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing ex vivo allogeneic CAR T therapies and in vivo therapies with its ARCUS® genome editing platform, today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary ... DTIL (Precision BioSciences Inc.): A Small Biotech Company with Fluctuating Earnings and Revenue Growth. DTIL (Precision BioSciences Inc.) is a biotechnology company that specializes in gene editing and gene therapy. On September 12, 2023, the stock opened at $0.41, slightly lower than the previous day’s closing price …After the upgrade, the consensus from Precision BioSciences' five analysts is for revenues of US$37m in 2023, which would reflect a chunky 20% decline in sales compared to the last year of ...This free interactive report on Precision BioSciences' balance sheet strength is a great place to start, if you want to investigate the stock further. A Different Perspective. Given that the market gained 5.6% in the last year, Precision BioSciences shareholders might be miffed that they lost 65%.Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update. November 7, 2023 at 7:00 AM EST. PDF Version ... Weighted average shares of common stock outstanding-basic and diluted 115,174,752 110,849,196 Precision Biosciences, Inc. Condensed Balance Sheets Data ...Stifel Nicolaus Adjusts Precision BioSciences Price Target to $9 From $11, Maintains Buy Rating. Goldman Sachs Adjusts Precision BioSciences' Price Target to $2 From $3, Keeps Neutral Rating. More news. Press releases Precision BioSciences, Inc. Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update.Jul 24, 2023 · Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Find out why I rate DTIL stock a Buy.

Track Precision Biosciences Inc (DTIL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsDTIL Precision BioSciences Inc Form 8-K - Current report. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...33,354.14. -0.10%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Precision BioSciences Inc (DTIL.O) real-time stock quotes, news, price and financial information from Reuters ...Instagram:https://instagram. iphone 15 ultra pre order90 day t billcurrency trading companiesqyld yield Get the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions. brokerage similar to robinhoodbest time of day to trade forex Nov 30, 2023 · Precision Biosciences’ stock performance can be influenced by factors such as market volatility, regulatory challenges, and competition within the gene editing industry. Investors should carefully evaluate these risks before making investment decisions. Precision Biosciences is at the forefront of the gene editing revolution, leveraging its ... Precision BioSciences Insider Transactions Over The Last Year. The Chief Financial Officer John Kelly made the biggest insider purchase in the last 12 months. That single transaction was for US ... falcon trading computers review About the Company. Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders.The Precision BioSciences Inc. stock price fell by -9.31% on the last day (Wednesday, 29th Nov 2023) from $0.408 to $0.370. During the last trading day the stock fluctuated 15.44% from a day low at $0.360 to a day high of $0.416. The price has risen in 6 of the last 10 days and is up by 6.78% over the past 2 weeks.Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced a promotion and organizational changes within the Company’s Senior Leadership Team (SLT).. The company announced the promotion of Neil …